Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (27 quarters reported)
$203M in Q4 2019 → $1.94B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Space Exploration Technologies Corp. | 93.7% | New | 10,644,340 | $1.82B |
| Twist Bioscience Corporation | 2.5% | Trimmed 42% | 478,815 | $49.3M |
| Tesla, Inc. | 1.9% | Unchanged | 86,250 | $36.3M |
| Hyatt Hotels Corporation | 0.7% | Unchanged | 70,000 | $13.6M |
| Madrigal Pharmaceuticals, Inc. | 0.6% | Unchanged | 21,000 | $11.3M |
| 10x Genomics, Inc. | 0.6% | Added 34% | 283,469 | $10.9M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Space Exploration Technologies Corp. | New | +10,644,340 | +$1.82B | 93.7% |
| Twist Bioscience Corporation | Trimmed | −350,000 | −$36M | 2.5% |
| Ouster, Inc. | Exited | −845,316 | −$15.5M | — |
| 908 Devices Inc. | Exited | −568,981 | −$3.48M | — |
| Warby Parker Inc. | Exited | −134,473 | −$2.83M | — |
| 10x Genomics, Inc. | Added | +72,607 | +$2.78M | 0.6% |
quarter ended March 31, 2026 · filed May 14, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. | Trimmed | −20,000 | −$11.6M | 10.5% |
| Ouster, Inc. | Trimmed | −280,000 | −$6.06M | 15.7% |
| Sonder Holdings Inc. | Exited | −80,188 | −$102K | — |
| Ginkgo Bioworks Holdings, Inc. | Exited | −5,683 | −$82.9K | — |
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. | Trimmed | −71,785 | −$32.9M | 14.2% |
| 10x Genomics, Inc. | New | +210,862 | +$2.46M | 1.9% |
quarter ended June 30, 2025 · filed August 12, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. | Trimmed | −17,744 | −$5.88M | 32.2% |
| BH Benson Hill, Inc. | Exited | −50,704 | −$99.9K | — |
quarter ended December 31, 2024 · filed February 13, 2025
No position changes this quarter.
quarter ended September 30, 2024 · filed November 08, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| BH Benson Hill, Inc. | New | +50,704 | +$365K | 0.3% |
| BH Benson Hill, Inc. | Exited | −1,774,681 | −$270K | — |
| Ginkgo Bioworks Holdings, Inc. | Exited | −227,354 | −$76K | — |
| Ginkgo Bioworks Holdings, Inc. | New | +5,683 | +$46.3K | — |
Loading...
